Refika Yigit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Refika Yigit has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Joost Bart
Department of Pathology, University Medical Centre Groningen, Groningen, The Netherlands
17 shared publications - Anneke L. Eerkens
University Medical Center Groningen 1 Department of Obstetrics and Gynaecology Groningen, the Netherlands
14 shared publications - Hans. W. Nijman
Department of Gynecology, University Medical Center Groningen, Groningen, The Netherlands
14 shared publications - Koen Brummel
University Medical Center Groningen 1 Department of Obstetrics and Gynaecology Groningen, the Netherlands
14 shared publications - Marco de Bruyn
Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Netherlands
14 shared publications - Annechien Plat
Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
13 shared publications
Latest Publications
- Open Access
- 22 August 2026
- Published by Elsevier in SSRN Electronic Journal
Fertility and pregnancy concerns and needs after fertility-sparing surgery in young women with gynecological cancer and their partners: a qualitative study
Introduction: Many young women treated for gynecological cancer are assumed to experience long-term concerns about fertility and pregnancy, and psychological distress. However, evidence on patients’ post-treatment reproductive concerns, decisions to pursue pregnancy, and oncofertility needs is limited. This study aims to provide insight into the perspectives of women treated with fertility-sparing surgery (FSS) for gynecological cancer and their partners.Methods: Women and their partners were selected for semi-structured interviews from our previously performed questionnaire study through purposive sampling based on self-reported reproductive concerns and pregnancy attempts.Results: Data saturation was achieved after 32 interviews with 24 women and eight partners. Three women refrained from pursuing pregnancy. Many women expressed reproductive concerns and encounter post-treatment challenges, including a sense of time pressure, fear of cancer recurrence, and a common need for assisted reproductive techniques. Nearly all women expressed their need for post-operative fertility counseling, although the preferred timing for this support varied. Partners considered their primary role as providing support throughout the treatment (decision) process, deciding to conceive and pursuing pregnancy. Some partners emphasized the importance, but lack of partner support.Conclusions: Women treated with FSS for gynecological cancer and their partners face persistent uncertainty regarding fertility and pregnancy, yet most women remain motivated to pursue pregnancy. Partners play a supportive role, but also have unmet needs. These findings highlight that reproductive issues should be systematically incorporated into routine clinical care pathways.
- 22 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFertility and pregnancy concerns and needs after fertility-sparing surgery in young women with gynecological cancer and their partners: a qualitative study
Introduction: Many young women treated for gynecological cancer are assumed to experience long-term concerns about fertility and pregnancy, and psychological distress. However, evidence on patients’ post-treatment reproductive concerns, decisions to pursue pregnancy, and oncofertility needs is limited. This study aims to provide insight into the perspectives of women treated with fertility-sparing surgery (FSS) for gynecological cancer and their partners.Methods: Women and their partners were selected for semi-structured interviews from our previously performed questionnaire study through purposive sampling based on self-reported reproductive concerns and pregnancy attempts.Results: Data saturation was achieved after 32 interviews with 24 women and eight partners. Three women refrained from pursuing pregnancy. Many women expressed reproductive concerns and encounter post-treatment challenges, including a sense of time pressure, fear of cancer recurrence, and a common need for assisted reproductive techniques. Nearly all women expressed their need for post-operative fertility counseling, although the preferred timing for this support varied. Partners considered their primary role as providing support throughout the treatment (decision) process, deciding to conceive and pursuing pregnancy. Some partners emphasized the importance, but lack of partner support.Conclusions: Women treated with FSS for gynecological cancer and their partners face persistent uncertainty regarding fertility and pregnancy, yet most women remain motivated to pursue pregnancy. Partners play a supportive role, but also have unmet needs. These findings highlight that reproductive issues should be systematically incorporated into routine clinical care pathways.
- Open Access
- 5 May 2025
- Published by Springer Nature in Familial Cancer
- Vol. 24 (2) , 1-8
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data
Identification of somatic and germline BRCA1/2 pathogenic variants in epithelial ovarian cancer (EOC) patients is essential for determining poly-(ADP-ribose)-polymerase (PARP) inhibitor sensitivity and genetic predisposition. In the Netherlands, BRCA1/2 testing changed to a tumor-first approach to efficiently identify both somatic and germline pathogenic variants in all patients. Here, we performed an in-depth evaluation of the first four years of the tumor-first test-pathway. Data of consecutive series of patients diagnosed with EOC in two regions were obtained from the Netherlands Cancer Registry. Tumor and/or germline test data were retrieved from hospital databases. The primary outcome was the percentage of patients completing the BRCA1/2 test-pathway, defined as having a negative tumor test or a referral for a germline test in case of a positive tumor test or no tumor test. Factors associated with test-pathway completion were identified through multivariable logistic regression analysis. In total, 69.8% (757/1085) completed the test-pathway. This was 74.4% in the most recent year. Younger patients, patients diagnosed in year three or four, patients with high-grade serous/high-grade endometrioid carcinoma, advanced stage disease, middle or high socioeconomic status, and patients who underwent surgery or chemotherapy, were more likely to complete the test-pathway. We report inequalities in genetic testing access in EOC patients, which highlight the need for better guideline adherence, particularly in older patients, those with low socioeconomic status, low-grade histotypes, early-stage disease and those without surgery or chemotherapy. Additionally, timely testing of patients, and testing relatives if patients cannot be tested, are crucial to increase test uptake.
- 5 May 2025
- Published by Springer Nature in Familial Cancer
- Vol. 24 (2) , 1-8
Open AccessEvaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data
Identification of somatic and germline BRCA1/2 pathogenic variants in epithelial ovarian cancer (EOC) patients is essential for determining poly-(ADP-ribose)-polymerase (PARP) inhibitor sensitivity and genetic predisposition. In the Netherlands, BRCA1/2 testing changed to a tumor-first approach to efficiently identify both somatic and germline pathogenic variants in all patients. Here, we performed an in-depth evaluation of the first four years of the tumor-first test-pathway. Data of consecutive series of patients diagnosed with EOC in two regions were obtained from the Netherlands Cancer Registry. Tumor and/or germline test data were retrieved from hospital databases. The primary outcome was the percentage of patients completing the BRCA1/2 test-pathway, defined as having a negative tumor test or a referral for a germline test in case of a positive tumor test or no tumor test. Factors associated with test-pathway completion were identified through multivariable logistic regression analysis. In total, 69.8% (757/1085) completed the test-pathway. This was 74.4% in the most recent year. Younger patients, patients diagnosed in year three or four, patients with high-grade serous/high-grade endometrioid carcinoma, advanced stage disease, middle or high socioeconomic status, and patients who underwent surgery or chemotherapy, were more likely to complete the test-pathway. We report inequalities in genetic testing access in EOC patients, which highlight the need for better guideline adherence, particularly in older patients, those with low socioeconomic status, low-grade histotypes, early-stage disease and those without surgery or chemotherapy. Additionally, timely testing of patients, and testing relatives if patients cannot be tested, are crucial to increase test uptake.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S2. Univariate Cox regression for histopathologic regression following Vvax001 immunizations.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S2. Univariate Cox regression for histopathologic regression following Vvax001 immunizations.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S6. CD3+ immune infiltration.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S6. CD3+ immune infiltration.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S3. Univariate Cox regression for HPV16 clearance following Vvax001 immunizations.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S3. Univariate Cox regression for HPV16 clearance following Vvax001 immunizations.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Data from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Purpose:Human papillomavirus (HPV) infection is the major cause of (pre)malignant cervical lesions. We previously demonstrated that Vvax001, a replication-incompetent Semliki Forest virus vaccine encoding HPV type 16 (HPV16) E6 and E7, induced potent anti-E6 and -E7 cytotoxic T-cell responses. In this study, we investigated the clinical efficacy of Vvax001 in patients with HPV16-positive cervical intraepithelial neoplasia (CIN) grade 3 (CIN3).Patients and Methods:Patients with newly diagnosed HPV16-positive CIN3 were eligible for participation. Patients received three immunizations of Vvax001 (5 × 107 infectious particles) at a 3-week interval. Up to 19 weeks after the last immunization, patients were monitored for regression of CIN3 by colposcopy. A colposcopy-guided biopsy was taken at the last visit, and a standard-of-care loop excision was performed only in case of remaining CIN grade 2/CIN3. Histopathologic response rates, HPV16 clearance, treatment-related adverse events, and vaccine-induced immune responses were assessed.Results:A total of 18 patients were enrolled and fully immunized. Colposcopic examination revealed a reduction in CIN3 lesion sizes in 17/18 (94%) patients already evident from 3 weeks onward after the last immunization. A histopathologic complete response (regression to CIN grade 1 or no dysplasia) was observed in 9/18 patients (50%) and HPV16 clearance in 10/16 patients (63%). Vvax001 did not induce clearance of other HPV types. To date, no recurrences have been observed, with a median and longest disease-free survival of 20 and 30 months, respectively. No serious adverse events were observed.Conclusions:Treatment with Vvax001 is safe and feasible and shows preliminary clinical effectiveness in patients with HPV16-associated CIN3 lesions.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Purpose:Human papillomavirus (HPV) infection is the major cause of (pre)malignant cervical lesions. We previously demonstrated that Vvax001, a replication-incompetent Semliki Forest virus vaccine encoding HPV type 16 (HPV16) E6 and E7, induced potent anti-E6 and -E7 cytotoxic T-cell responses. In this study, we investigated the clinical efficacy of Vvax001 in patients with HPV16-positive cervical intraepithelial neoplasia (CIN) grade 3 (CIN3).Patients and Methods:Patients with newly diagnosed HPV16-positive CIN3 were eligible for participation. Patients received three immunizations of Vvax001 (5 × 107 infectious particles) at a 3-week interval. Up to 19 weeks after the last immunization, patients were monitored for regression of CIN3 by colposcopy. A colposcopy-guided biopsy was taken at the last visit, and a standard-of-care loop excision was performed only in case of remaining CIN grade 2/CIN3. Histopathologic response rates, HPV16 clearance, treatment-related adverse events, and vaccine-induced immune responses were assessed.Results:A total of 18 patients were enrolled and fully immunized. Colposcopic examination revealed a reduction in CIN3 lesion sizes in 17/18 (94%) patients already evident from 3 weeks onward after the last immunization. A histopathologic complete response (regression to CIN grade 1 or no dysplasia) was observed in 9/18 patients (50%) and HPV16 clearance in 10/16 patients (63%). Vvax001 did not induce clearance of other HPV types. To date, no recurrences have been observed, with a median and longest disease-free survival of 20 and 30 months, respectively. No serious adverse events were observed.Conclusions:Treatment with Vvax001 is safe and feasible and shows preliminary clinical effectiveness in patients with HPV16-associated CIN3 lesions.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Fig. S4. Intraepithelial and subepithelial CD8+ T cell infiltration relative to CD3+ T cell infiltration.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Fig. S4. Intraepithelial and subepithelial CD8+ T cell infiltration relative to CD3+ T cell infiltration.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S5. CD19+ immune infiltration.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Table S5. CD19+ immune infiltration.
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Fig. S2. Swimmer plot depicting per patient the timeline of follow-up, requirement of LLETZ, HPV16 clearance and recurrence (N = 18).
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Fig. S2. Swimmer plot depicting per patient the timeline of follow-up, requirement of LLETZ, HPV16 clearance and recurrence (N = 18).
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Fig. S1. Schematic overview of rSFV vector encoding the eE6,7 fusion protein.
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial
Supplementary Fig. S1. Schematic overview of rSFV vector encoding the eE6,7 fusion protein.